Diamyd is under clinical development by Diamyd Medical and currently in Phase II for Latent Autoimmune Diabetes of Adulthood (LADA)/ Type 1.5 Diabetes. According to GlobalData, Phase II drugs for Latent Autoimmune Diabetes of Adulthood (LADA)/ Type 1.5 Diabetes does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Diamyd LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diamyd overview

Diamyd is under development for the treatment of LADA (latent autoimmune diabetes in adults), prevention and treatment of type 1 diabetes. Diamyd is administered as a subcutaneous, intra-inguinal injection and intralymphatic injection. Diamyd consists of recombinant human GAD65 which acts by targeting pancreatic beta cell autoantigen in autoimmune diabetes. It is developed based on GAD platform.

Diamyd Medical overview

Diamyd Medical (Diamyd), formerly Diamyd Therapeutics, is a drug development company that offers diabetes vaccines. The company’s diabetes products include Diamyd and Remygen. The company product Diamyd is antigen-based immunotherapy. Its other product include remygen is a regenerative and immunomodulatory therapy. The company products are use for the treatment of autoimmune diabetes. Its products are in the clinical stage, Diamyd is at III stages and remygen is at II stage of development. The company drug have to pass several development stages such as preclinical and clinical phases. It does clinical trails of rugs in its facilities at Stockholm and umea, Sweden. Diamyd is headquartered in Stockholm, Sweden.

For a complete picture of Diamyd’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.